Giovanni Marchegiani, Academic surgeon at Padova University Hospital, shared a post about a paper by Xueli Bai et al. Published on A Cell Press Journal.
“The kiss between nab-paclitaxel / gem and FOLFINIRNOX ?!
Neoadjuvant regimens combined in resectable.
RCT 324 pts vs. Upfront surgery median EFS 15 vs. 10 months?
Doubts about control group, but again in the direction of neoadjuvant to all!”
Title: Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial
Authors: Xueli Bai, Xiang Li, Yiwen Chen, Guoliang Qiao, Qi Zhang, Tao Ma, Shunliang Gao, Min Zhang, Yan Shen, Jian Wu, Jun Yu, Risheng Que, Xiaochen Zhang, Ke Sun, Wenbo Xiao, Tian’an Jiang, Tingbo Liang
Read the full article on A Cell Press Journal.
More posts featuring Giovanni Marchegiani on OncoDaily.
